Figure 5: iPSCs increase the survival rate and motor activity of recipient mice. Male BALB/c mice were used for evaluation of the hepatoprotective activity of iPSC in the TAA-treated liver injury model. TAA (150 mg/kg) was given via intra-peritoneum injection and mice were received PBS or iPSCs (2 × 106 cells) via tail vein injection to determinate (a) the survival rate and (b) motor movements. Data shown here are the mean ± SD. * versus PBS.